http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 10 Jun 2026 09:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Announces+Release+of+New+CEO+Corner+Segment+Highlighting+Global+Scientific+and+Clinical+Recognition+of+Platform+Technology/26627762.html <p align="center"><i>Access the segment </i><a href="https://www.globenewswire.com/Tracker?data=wQmoUdv57oMLbom36-qRFS_GYJId9aQTRAE2dbCpGjfuHSu5UEH9Lu2LEU06SqrqZT8MlXpdwJllnlMmIwPs3NzNlz3hMy8IqnUJDnklWVg=" rel="nofollow" target="_blank"><i>here</i></a></p> <p align="justify"><b>THE WOODLANDS, TX, June 10, 2026 (GLOBE NEWSWIRE) -- </b><a href="https://www.globenewswire.com/Tracker?data=yiRYyWSGnr_TPpUpVzG8Xq1WH_nk7KFGBk8nbMh3-_TuUrs_2ReIV-HIYaVgBS2ciQIOFODFbzpR2mJQGPaq6Q7VZ_AHlZT9LMvB5QukNm6nPbY9p1_BROApVWVU6GQeMViAJOoQPe7fMBizcFlHuOVlAerUeu1X_od5Au2lzXfAQ04qJ35BQzeZEan9X95bHaDHQ_65S-o4iIdYkWDJqfiaaOFD_Z6vW_QncHeu6Tcpni_uozbLk3IBAuZnm4i4evMkiUEs2dnf9LRWdqL4Gg==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest <a href="https://www.globenewswire.com/Tracker?data=UlZin_Zoj5_ch2dotKOHjzCsU91S9zg0hGfACAXSzp4BOzYV2oCsTcXuMkhuA5jUtsLRyM0fR8z2hP-43vH2wT8idZAoLIhzEcpFjQu5QpRrzKX0GtAcyNZuISe2cKzi" rel="nofollow" target="_blank">CEO Corner segment</a> featuring President and Chief Executive Officer, Brad Hauser.</p> <p align="justify">As part of the segment, Mr. Hauser highlights the Company’s growing scientific and clinical recognition as its differentiated nerve-sensing and transvascular denervation platform gains traction across leading global medical conferences. Mr. Hauser highlighted that since last http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Announces+Release+of+New+CEO+Corner+Segment+Highlighting+Global+Scientific+and+Clinical+Recognition+of+Platform+Technology/26627762.html Wed, 10 Jun 2026 09:05:00 -0400 AMIX http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Announces+Release+of+New+CEO+Corner+Segment+Highlighting+Global+Scientific+and+Clinical+Recognition+of+Platform+Technology/26627762.html <p align="center"><i>Access the segment </i><a href="https://www.globenewswire.com/Tracker?data=wQmoUdv57oMLbom36-qRFS_GYJId9aQTRAE2dbCpGjfuHSu5UEH9Lu2LEU06SqrqZT8MlXpdwJllnlMmIwPs3NzNlz3hMy8IqnUJDnklWVg=" rel="nofollow" target="_blank"><i>here</i></a></p> <p align="justify"><b>THE WOODLANDS, TX, June 10, 2026 (GLOBE NEWSWIRE) -- </b><a href="https://www.globenewswire.com/Tracker?data=yiRYyWSGnr_TPpUpVzG8Xq1WH_nk7KFGBk8nbMh3-_TuUrs_2ReIV-HIYaVgBS2ciQIOFODFbzpR2mJQGPaq6Q7VZ_AHlZT9LMvB5QukNm6nPbY9p1_BROApVWVU6GQeMViAJOoQPe7fMBizcFlHuOVlAerUeu1X_od5Au2lzXfAQ04qJ35BQzeZEan9X95bHaDHQ_65S-o4iIdYkWDJqfiaaOFD_Z6vW_QncHeu6Tcpni_uozbLk3IBAuZnm4i4evMkiUEs2dnf9LRWdqL4Gg==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest <a href="https://www.globenewswire.com/Tracker?data=UlZin_Zoj5_ch2dotKOHjzCsU91S9zg0hGfACAXSzp4BOzYV2oCsTcXuMkhuA5jUtsLRyM0fR8z2hP-43vH2wT8idZAoLIhzEcpFjQu5QpRrzKX0GtAcyNZuISe2cKzi" rel="nofollow" target="_blank">CEO Corner segment</a> featuring President and Chief Executive Officer, Brad Hauser.</p> <p align="justify">As part of the segment, Mr. Hauser highlights the Company’s growing scientific and clinical recognition as its differentiated nerve-sensing and transvascular denervation platform gains traction across leading global medical conferences. Mr. Hauser highlighted that since last http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Announces+Release+of+New+CEO+Corner+Segment+Highlighting+Global+Scientific+and+Clinical+Recognition+of+Platform+Technology/26627762.html Wed, 10 Jun 2026 09:05:00 -0400 AMIX http://www.streetinsider.com/Corporate+News/Autonomix+Medical+discusses+pancreatic+cancer+pain+data+in+investor+segment/26603426.html <p>Autonomix Medical Inc. (NASDAQ: AMIX) participated in a virtual investor segment featuring Dr. Toufic Kachaamy, Chief of Medicine at City of Hope in Phoenix, to discuss clinical data presented at the Society of Surgical Oncology Annual Meeting.</p><p>The segment addressed Autonomix's approach to managing visceral cancer pain and how it differs from existing treatment methods. Dr. Kachaamy discussed the clinical significance of the company's data being selected for a podium presentation at the surgical oncology meeting.</p><p>The discussion covered the potential applicability of the findings beyond pancreatic cancer and how the results support ongoing clinical development of the technology platform. Dr. Kachaamy http://www.streetinsider.com/Corporate+News/Autonomix+Medical+discusses+pancreatic+cancer+pain+data+in+investor+segment/26603426.html Thu, 04 Jun 2026 09:05:31 -0400 AMIX http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%22What+This+Means%22+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603411.html <p align="center"><i>Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential </i></p> <p align="center"><i>Access the segment </i><a href="https://www.globenewswire.com/Tracker?data=CPPZU5VnSQA8w3-nzqQfqMDhS_3FeR_fPpusINa6qZEETHzcC7HikSjnOlxlKC5cwsjuzU20CIsfsL5_ShM-1xmVs49caYJfnvTlPFoum14=" rel="nofollow" target="_blank"><i>here</i></a><br /></p> <p align="justify"><b>THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- </b><a href="https://www.globenewswire.com/Tracker?data=nKeOFWJVjIVDmqNCEvwKYqTw7gkLycd39mPnqy-5-3d0xqulNAfonnIcFAqAtHvR5uXLC164_oO-SkHPGPCpYJlx7QDcq9txcTQXZml4_kQ-b27_xeolRx7UmVnaGOGtkhVAQPOMEPlmpUrC59bLkftmR2WERQOjH9hwW2E2iZCDrGndbebvOBzpSGPXDZZ5yu9VMOeqxulk2Qtzs5CQQBtKsChJnTQm4zv-2oEfO9_qBsterPAQ1m2Fhz-Ld2XMzmvtJ5sni0PSdO9-_a7iMw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a <a href="https://www.globenewswire.com/Tracker?data=biTAc5aTVAmb7o2NStci8km7aM-xE_vE4soz5q5-CdLQwAwTA31qN3q-IQeqg7-kbOJSZXt9ZSJiRAVqfknr593szEbPiEH5G-FcrmhfxfTigKhPiFAX4EGAoN6q0wD4haUtT0gfkYw5-dijs3LzhA==" rel="nofollow" target="_blank">Virtual Investor “What This Means”</a> segment.</p> <p align="justify">For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, Dr. Toufic http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%22What+This+Means%22+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603411.html Thu, 04 Jun 2026 09:05:00 -0400 AMIX http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%22What+This+Means%22+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603411.html <p align="center"><i>Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential </i></p> <p align="center"><i>Access the segment </i><a href="https://www.globenewswire.com/Tracker?data=CPPZU5VnSQA8w3-nzqQfqMDhS_3FeR_fPpusINa6qZEETHzcC7HikSjnOlxlKC5cwsjuzU20CIsfsL5_ShM-1xmVs49caYJfnvTlPFoum14=" rel="nofollow" target="_blank"><i>here</i></a><br /></p> <p align="justify"><b>THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- </b><a href="https://www.globenewswire.com/Tracker?data=nKeOFWJVjIVDmqNCEvwKYqTw7gkLycd39mPnqy-5-3d0xqulNAfonnIcFAqAtHvR5uXLC164_oO-SkHPGPCpYJlx7QDcq9txcTQXZml4_kQ-b27_xeolRx7UmVnaGOGtkhVAQPOMEPlmpUrC59bLkftmR2WERQOjH9hwW2E2iZCDrGndbebvOBzpSGPXDZZ5yu9VMOeqxulk2Qtzs5CQQBtKsChJnTQm4zv-2oEfO9_qBsterPAQ1m2Fhz-Ld2XMzmvtJ5sni0PSdO9-_a7iMw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a <a href="https://www.globenewswire.com/Tracker?data=biTAc5aTVAmb7o2NStci8km7aM-xE_vE4soz5q5-CdLQwAwTA31qN3q-IQeqg7-kbOJSZXt9ZSJiRAVqfknr593szEbPiEH5G-FcrmhfxfTigKhPiFAX4EGAoN6q0wD4haUtT0gfkYw5-dijs3LzhA==" rel="nofollow" target="_blank">Virtual Investor “What This Means”</a> segment.</p> <p align="justify">For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, Dr. Toufic http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%22What+This+Means%22+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603411.html Thu, 04 Jun 2026 09:05:00 -0400 AMIX http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html <p align="center"><i>Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential </i></p> <p align="center"><i>Access the segment </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=CPPZU5VnSQA8w3-nzqQfqMDhS_3FeR_fPpusINa6qZEETHzcC7HikSjnOlxlKC5cwsjuzU20CIsfsL5_ShM-1xmVs49caYJfnvTlPFoum14=" rel="nofollow" target="_blank"><i>here</i></a><br/></p> <p align="justify"><b>THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=nKeOFWJVjIVDmqNCEvwKYqTw7gkLycd39mPnqy-5-3d0xqulNAfonnIcFAqAtHvR5uXLC164_oO-SkHPGPCpYJlx7QDcq9txcTQXZml4_kQ-b27_xeolRx7UmVnaGOGtkhVAQPOMEPlmpUrC59bLkftmR2WERQOjH9hwW2E2iZCDrGndbebvOBzpSGPXDZZ5yu9VMOeqxulk2Qtzs5CQQBtKsChJnTQm4zv-2oEfO9_qBsterPAQ1m2Fhz-Ld2XMzmvtJ5sni0PSdO9-_a7iMw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=biTAc5aTVAmb7o2NStci8km7aM-xE_vE4soz5q5-CdLQwAwTA31qN3q-IQeqg7-kbOJSZXt9ZSJiRAVqfknr593szEbPiEH5G-FcrmhfxfTigKhPiFAX4EGAoN6q0wD4haUtT0gfkYw5-dijs3LzhA==" rel="nofollow" target="_blank">Virtual Investor “What This Means”</a> segment.</p> <p align="justify">For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html Thu, 04 Jun 2026 09:05:00 -0400 A.50200982 AMIX O.00081842 O.58324469 http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html <p align="center"><i>Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential </i></p> <p align="center"><i>Access the segment </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=CPPZU5VnSQA8w3-nzqQfqMDhS_3FeR_fPpusINa6qZEETHzcC7HikSjnOlxlKC5cwsjuzU20CIsfsL5_ShM-1xmVs49caYJfnvTlPFoum14=" rel="nofollow" target="_blank"><i>here</i></a><br/></p> <p align="justify"><b>THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=nKeOFWJVjIVDmqNCEvwKYqTw7gkLycd39mPnqy-5-3d0xqulNAfonnIcFAqAtHvR5uXLC164_oO-SkHPGPCpYJlx7QDcq9txcTQXZml4_kQ-b27_xeolRx7UmVnaGOGtkhVAQPOMEPlmpUrC59bLkftmR2WERQOjH9hwW2E2iZCDrGndbebvOBzpSGPXDZZ5yu9VMOeqxulk2Qtzs5CQQBtKsChJnTQm4zv-2oEfO9_qBsterPAQ1m2Fhz-Ld2XMzmvtJ5sni0PSdO9-_a7iMw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=biTAc5aTVAmb7o2NStci8km7aM-xE_vE4soz5q5-CdLQwAwTA31qN3q-IQeqg7-kbOJSZXt9ZSJiRAVqfknr593szEbPiEH5G-FcrmhfxfTigKhPiFAX4EGAoN6q0wD4haUtT0gfkYw5-dijs3LzhA==" rel="nofollow" target="_blank">Virtual Investor “What This Means”</a> segment.</p> <p align="justify">For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html Thu, 04 Jun 2026 09:05:00 -0400 A.50200982 AMIX O.00081842 O.58324469 http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html <p align="center"><i>Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential </i></p> <p align="center"><i>Access the segment </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=CPPZU5VnSQA8w3-nzqQfqMDhS_3FeR_fPpusINa6qZEETHzcC7HikSjnOlxlKC5cwsjuzU20CIsfsL5_ShM-1xmVs49caYJfnvTlPFoum14=" rel="nofollow" target="_blank"><i>here</i></a><br/></p> <p align="justify"><b>THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=nKeOFWJVjIVDmqNCEvwKYqTw7gkLycd39mPnqy-5-3d0xqulNAfonnIcFAqAtHvR5uXLC164_oO-SkHPGPCpYJlx7QDcq9txcTQXZml4_kQ-b27_xeolRx7UmVnaGOGtkhVAQPOMEPlmpUrC59bLkftmR2WERQOjH9hwW2E2iZCDrGndbebvOBzpSGPXDZZ5yu9VMOeqxulk2Qtzs5CQQBtKsChJnTQm4zv-2oEfO9_qBsterPAQ1m2Fhz-Ld2XMzmvtJ5sni0PSdO9-_a7iMw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=biTAc5aTVAmb7o2NStci8km7aM-xE_vE4soz5q5-CdLQwAwTA31qN3q-IQeqg7-kbOJSZXt9ZSJiRAVqfknr593szEbPiEH5G-FcrmhfxfTigKhPiFAX4EGAoN6q0wD4haUtT0gfkYw5-dijs3LzhA==" rel="nofollow" target="_blank">Virtual Investor “What This Means”</a> segment.</p> <p align="justify">For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html Thu, 04 Jun 2026 09:05:00 -0400 A.50200982 AMIX O.00081842 O.58324469 http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html <p align="center"><i>Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential </i></p> <p align="center"><i>Access the segment </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=CPPZU5VnSQA8w3-nzqQfqMDhS_3FeR_fPpusINa6qZEETHzcC7HikSjnOlxlKC5cwsjuzU20CIsfsL5_ShM-1xmVs49caYJfnvTlPFoum14=" rel="nofollow" target="_blank"><i>here</i></a><br/></p> <p align="justify"><b>THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=nKeOFWJVjIVDmqNCEvwKYqTw7gkLycd39mPnqy-5-3d0xqulNAfonnIcFAqAtHvR5uXLC164_oO-SkHPGPCpYJlx7QDcq9txcTQXZml4_kQ-b27_xeolRx7UmVnaGOGtkhVAQPOMEPlmpUrC59bLkftmR2WERQOjH9hwW2E2iZCDrGndbebvOBzpSGPXDZZ5yu9VMOeqxulk2Qtzs5CQQBtKsChJnTQm4zv-2oEfO9_qBsterPAQ1m2Fhz-Ld2XMzmvtJ5sni0PSdO9-_a7iMw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=biTAc5aTVAmb7o2NStci8km7aM-xE_vE4soz5q5-CdLQwAwTA31qN3q-IQeqg7-kbOJSZXt9ZSJiRAVqfknr593szEbPiEH5G-FcrmhfxfTigKhPiFAX4EGAoN6q0wD4haUtT0gfkYw5-dijs3LzhA==" rel="nofollow" target="_blank">Virtual Investor “What This Means”</a> segment.</p> <p align="justify">For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html Thu, 04 Jun 2026 09:05:00 -0400 A.50200982 AMIX O.00081842 O.58324469 http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html <p align="center"><i>Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential </i></p> <p align="center"><i>Access the segment </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=CPPZU5VnSQA8w3-nzqQfqMDhS_3FeR_fPpusINa6qZEETHzcC7HikSjnOlxlKC5cwsjuzU20CIsfsL5_ShM-1xmVs49caYJfnvTlPFoum14=" rel="nofollow" target="_blank"><i>here</i></a><br/></p> <p align="justify"><b>THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=nKeOFWJVjIVDmqNCEvwKYqTw7gkLycd39mPnqy-5-3d0xqulNAfonnIcFAqAtHvR5uXLC164_oO-SkHPGPCpYJlx7QDcq9txcTQXZml4_kQ-b27_xeolRx7UmVnaGOGtkhVAQPOMEPlmpUrC59bLkftmR2WERQOjH9hwW2E2iZCDrGndbebvOBzpSGPXDZZ5yu9VMOeqxulk2Qtzs5CQQBtKsChJnTQm4zv-2oEfO9_qBsterPAQ1m2Fhz-Ld2XMzmvtJ5sni0PSdO9-_a7iMw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=biTAc5aTVAmb7o2NStci8km7aM-xE_vE4soz5q5-CdLQwAwTA31qN3q-IQeqg7-kbOJSZXt9ZSJiRAVqfknr593szEbPiEH5G-FcrmhfxfTigKhPiFAX4EGAoN6q0wD4haUtT0gfkYw5-dijs3LzhA==" rel="nofollow" target="_blank">Virtual Investor “What This Means”</a> segment.</p> <p align="justify">For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html Thu, 04 Jun 2026 09:05:00 -0400 A.50200982 AMIX O.00081842 O.58324469 http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html <p align="center"><i>Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential </i></p> <p align="center"><i>Access the segment </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=CPPZU5VnSQA8w3-nzqQfqMDhS_3FeR_fPpusINa6qZEETHzcC7HikSjnOlxlKC5cwsjuzU20CIsfsL5_ShM-1xmVs49caYJfnvTlPFoum14=" rel="nofollow" target="_blank"><i>here</i></a><br/></p> <p align="justify"><b>THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=nKeOFWJVjIVDmqNCEvwKYqTw7gkLycd39mPnqy-5-3d0xqulNAfonnIcFAqAtHvR5uXLC164_oO-SkHPGPCpYJlx7QDcq9txcTQXZml4_kQ-b27_xeolRx7UmVnaGOGtkhVAQPOMEPlmpUrC59bLkftmR2WERQOjH9hwW2E2iZCDrGndbebvOBzpSGPXDZZ5yu9VMOeqxulk2Qtzs5CQQBtKsChJnTQm4zv-2oEfO9_qBsterPAQ1m2Fhz-Ld2XMzmvtJ5sni0PSdO9-_a7iMw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=biTAc5aTVAmb7o2NStci8km7aM-xE_vE4soz5q5-CdLQwAwTA31qN3q-IQeqg7-kbOJSZXt9ZSJiRAVqfknr593szEbPiEH5G-FcrmhfxfTigKhPiFAX4EGAoN6q0wD4haUtT0gfkYw5-dijs3LzhA==" rel="nofollow" target="_blank">Virtual Investor “What This Means”</a> segment.</p> <p align="justify">For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html Thu, 04 Jun 2026 09:05:00 -0400 A.50200982 AMIX O.00081842 O.58324469 http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html <p align="center"><i>Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential </i></p> <p align="center"><i>Access the segment </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=CPPZU5VnSQA8w3-nzqQfqMDhS_3FeR_fPpusINa6qZEETHzcC7HikSjnOlxlKC5cwsjuzU20CIsfsL5_ShM-1xmVs49caYJfnvTlPFoum14=" rel="nofollow" target="_blank"><i>here</i></a><br/></p> <p align="justify"><b>THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=nKeOFWJVjIVDmqNCEvwKYqTw7gkLycd39mPnqy-5-3d0xqulNAfonnIcFAqAtHvR5uXLC164_oO-SkHPGPCpYJlx7QDcq9txcTQXZml4_kQ-b27_xeolRx7UmVnaGOGtkhVAQPOMEPlmpUrC59bLkftmR2WERQOjH9hwW2E2iZCDrGndbebvOBzpSGPXDZZ5yu9VMOeqxulk2Qtzs5CQQBtKsChJnTQm4zv-2oEfO9_qBsterPAQ1m2Fhz-Ld2XMzmvtJ5sni0PSdO9-_a7iMw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=biTAc5aTVAmb7o2NStci8km7aM-xE_vE4soz5q5-CdLQwAwTA31qN3q-IQeqg7-kbOJSZXt9ZSJiRAVqfknr593szEbPiEH5G-FcrmhfxfTigKhPiFAX4EGAoN6q0wD4haUtT0gfkYw5-dijs3LzhA==" rel="nofollow" target="_blank">Virtual Investor “What This Means”</a> segment.</p> <p align="justify">For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html Thu, 04 Jun 2026 09:05:00 -0400 A.50200982 AMIX O.00081842 O.58324469 http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html <p align="center"><i>Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential </i></p> <p align="center"><i>Access the segment </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=CPPZU5VnSQA8w3-nzqQfqMDhS_3FeR_fPpusINa6qZEETHzcC7HikSjnOlxlKC5cwsjuzU20CIsfsL5_ShM-1xmVs49caYJfnvTlPFoum14=" rel="nofollow" target="_blank"><i>here</i></a><br/></p> <p align="justify"><b>THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=nKeOFWJVjIVDmqNCEvwKYqTw7gkLycd39mPnqy-5-3d0xqulNAfonnIcFAqAtHvR5uXLC164_oO-SkHPGPCpYJlx7QDcq9txcTQXZml4_kQ-b27_xeolRx7UmVnaGOGtkhVAQPOMEPlmpUrC59bLkftmR2WERQOjH9hwW2E2iZCDrGndbebvOBzpSGPXDZZ5yu9VMOeqxulk2Qtzs5CQQBtKsChJnTQm4zv-2oEfO9_qBsterPAQ1m2Fhz-Ld2XMzmvtJ5sni0PSdO9-_a7iMw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=biTAc5aTVAmb7o2NStci8km7aM-xE_vE4soz5q5-CdLQwAwTA31qN3q-IQeqg7-kbOJSZXt9ZSJiRAVqfknr593szEbPiEH5G-FcrmhfxfTigKhPiFAX4EGAoN6q0wD4haUtT0gfkYw5-dijs3LzhA==" rel="nofollow" target="_blank">Virtual Investor “What This Means”</a> segment.</p> <p align="justify">For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Highlights+Clinical+Data+Presented+at+Society+of+Surgical+Oncology+Annual+Meeting+in+Virtual+Investor+%26quot%3BWhat+This+Means%26quot%3B+Segment+Featuring+City+of+Hope+Chief+of+Medicine/26603415.html Thu, 04 Jun 2026 09:05:00 -0400 A.50200982 AMIX O.00081842 O.58324469 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Autonomix+Medical%2C+Inc.+++For%3A+Mar+31/26558430.html si-local-file:///var/storage/secattach/20260527/26558430.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Autonomix+Medical%2C+Inc.+++For%3A+Mar+31/26558430.html Wed, 27 May 2026 16:31:00 -0400 AMIX O.58324469 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Autonomix+Medical%2C+Inc.+++For%3A+Mar+31/26558430.html si-local-file:///var/storage/secattach/20260527/26558430.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Autonomix+Medical%2C+Inc.+++For%3A+Mar+31/26558430.html Wed, 27 May 2026 16:31:00 -0400 AMIX O.58324469 http://www.streetinsider.com/Corporate+News/Autonomix+Medical+receives+US+patent+for+transvascular+monitoring+system/26517938.html <p>Autonomix Medical Inc. (NASDAQ: AMIX) announced the U.S. Patent and Trademark Office issued Patent No. 12,544,131 for systems that monitor and treat tissues within and through lumen walls. The patent covers catheter-based transvascular tools designed to operate from within bodily lumens, with deployable probes that penetrate vessel walls to access external tissues and nerves.</p> <p>The patent includes claims for multi-site electrophysiological sensing at target, secondary, and reference sites to improve signal quality. It encompasses methods for assessing procedural completion based on electrophysiological signal processing, including detection of changes in neural activity patterns to evaluate treatment effects.</p> <p>"Current catheter-based neuromodulation procedures often lack http://www.streetinsider.com/Corporate+News/Autonomix+Medical+receives+US+patent+for+transvascular+monitoring+system/26517938.html Tue, 19 May 2026 08:30:32 -0400 AMIX O.58324469 http://www.streetinsider.com/Corporate+News/Autonomix+Medical+receives+US+patent+for+transvascular+monitoring+system/26517938.html <p>Autonomix Medical Inc. (NASDAQ: AMIX) announced the U.S. Patent and Trademark Office issued Patent No. 12,544,131 for systems that monitor and treat tissues within and through lumen walls. The patent covers catheter-based transvascular tools designed to operate from within bodily lumens, with deployable probes that penetrate vessel walls to access external tissues and nerves.</p> <p>The patent includes claims for multi-site electrophysiological sensing at target, secondary, and reference sites to improve signal quality. It encompasses methods for assessing procedural completion based on electrophysiological signal processing, including detection of changes in neural activity patterns to evaluate treatment effects.</p> <p>"Current catheter-based neuromodulation procedures often lack http://www.streetinsider.com/Corporate+News/Autonomix+Medical+receives+US+patent+for+transvascular+monitoring+system/26517938.html Tue, 19 May 2026 08:30:32 -0400 AMIX O.58324469 http://www.streetinsider.com/Press+Releases/Autonomix+Medical%2C+Inc.+Granted+U.S.+Patent+for+Transvascular+Monitoring+and+Treatment+Systems+with+Real-Time+Procedural+Validation/26517913.html <p align="center"><i>Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall</i></p> <p align="center"><i>Patent strengthens intellectual property foundation for next-generation neuromodulation technologies</i></p> <p align="justify"><b>THE WOODLANDS, TX, May 19, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Ec_nIhm0slMvZRXaH3qBJZppbBMMOdAyqzDaJj9zJwtpp3xWXAvHqJd-LarRIuK8bkIZ2bCGIcSseSMG-tMdiEjsRkD_K7S2UpwyLW6UGqMsJ19OgmlH14DOTPNBnVnmJfrvJ6Q_wqUHHK18SAbnt-U6y_67Gh3Vb0TWYNpvAmwHLMlB0ZgEQpVY3fAA8RT9FhyfxHxaIFm3WDzf9AlJhv8ytMwX67RZq3EBwiZZSSUUBH-ul61fA9UfxWBVSkFQ-iioCGSlJ_I0GlM6huZVvg==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,544,131 (the “131 patent”), titled “<i>Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall</i>.”</p> http://www.streetinsider.com/Press+Releases/Autonomix+Medical%2C+Inc.+Granted+U.S.+Patent+for+Transvascular+Monitoring+and+Treatment+Systems+with+Real-Time+Procedural+Validation/26517913.html Tue, 19 May 2026 08:30:00 -0400 AMIX O.58324469 http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical%2C+Inc.+Granted+U.S.+Patent+for+Transvascular+Monitoring+and+Treatment+Systems+with+Real-Time+Procedural+Validation/26517913.html <p align="center"><i>Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall</i></p> <p align="center"><i>Patent strengthens intellectual property foundation for next-generation neuromodulation technologies</i></p> <p align="justify"><b>THE WOODLANDS, TX, May 19, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Ec_nIhm0slMvZRXaH3qBJZppbBMMOdAyqzDaJj9zJwtpp3xWXAvHqJd-LarRIuK8bkIZ2bCGIcSseSMG-tMdiEjsRkD_K7S2UpwyLW6UGqMsJ19OgmlH14DOTPNBnVnmJfrvJ6Q_wqUHHK18SAbnt-U6y_67Gh3Vb0TWYNpvAmwHLMlB0ZgEQpVY3fAA8RT9FhyfxHxaIFm3WDzf9AlJhv8ytMwX67RZq3EBwiZZSSUUBH-ul61fA9UfxWBVSkFQ-iioCGSlJ_I0GlM6huZVvg==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,544,131 (the “131 patent”), titled “<i>Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall</i>.”</p> http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical%2C+Inc.+Granted+U.S.+Patent+for+Transvascular+Monitoring+and+Treatment+Systems+with+Real-Time+Procedural+Validation/26517913.html Tue, 19 May 2026 08:30:00 -0400 AMIX O.58324469 http://www.streetinsider.com/Press+Releases/Autonomix+Medical%2C+Inc.+Granted+U.S.+Patent+for+Transvascular+Monitoring+and+Treatment+Systems+with+Real-Time+Procedural+Validation/26517913.html <p align="center"><i>Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall</i></p> <p align="center"><i>Patent strengthens intellectual property foundation for next-generation neuromodulation technologies</i></p> <p align="justify"><b>THE WOODLANDS, TX, May 19, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Ec_nIhm0slMvZRXaH3qBJZppbBMMOdAyqzDaJj9zJwtpp3xWXAvHqJd-LarRIuK8bkIZ2bCGIcSseSMG-tMdiEjsRkD_K7S2UpwyLW6UGqMsJ19OgmlH14DOTPNBnVnmJfrvJ6Q_wqUHHK18SAbnt-U6y_67Gh3Vb0TWYNpvAmwHLMlB0ZgEQpVY3fAA8RT9FhyfxHxaIFm3WDzf9AlJhv8ytMwX67RZq3EBwiZZSSUUBH-ul61fA9UfxWBVSkFQ-iioCGSlJ_I0GlM6huZVvg==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,544,131 (the “131 patent”), titled “<i>Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall</i>.”</p> http://www.streetinsider.com/Press+Releases/Autonomix+Medical%2C+Inc.+Granted+U.S.+Patent+for+Transvascular+Monitoring+and+Treatment+Systems+with+Real-Time+Procedural+Validation/26517913.html Tue, 19 May 2026 08:30:00 -0400 AMIX O.58324469 http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical%2C+Inc.+Granted+U.S.+Patent+for+Transvascular+Monitoring+and+Treatment+Systems+with+Real-Time+Procedural+Validation/26517913.html <p align="center"><i>Technology unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall</i></p> <p align="center"><i>Patent strengthens intellectual property foundation for next-generation neuromodulation technologies</i></p> <p align="justify"><b>THE WOODLANDS, TX, May 19, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=Ec_nIhm0slMvZRXaH3qBJZppbBMMOdAyqzDaJj9zJwtpp3xWXAvHqJd-LarRIuK8bkIZ2bCGIcSseSMG-tMdiEjsRkD_K7S2UpwyLW6UGqMsJ19OgmlH14DOTPNBnVnmJfrvJ6Q_wqUHHK18SAbnt-U6y_67Gh3Vb0TWYNpvAmwHLMlB0ZgEQpVY3fAA8RT9FhyfxHxaIFm3WDzf9AlJhv8ytMwX67RZq3EBwiZZSSUUBH-ul61fA9UfxWBVSkFQ-iioCGSlJ_I0GlM6huZVvg==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,544,131 (the “131 patent”), titled “<i>Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall</i>.”</p> http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical%2C+Inc.+Granted+U.S.+Patent+for+Transvascular+Monitoring+and+Treatment+Systems+with+Real-Time+Procedural+Validation/26517913.html Tue, 19 May 2026 08:30:00 -0400 AMIX O.58324469 http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Announces+Abstract+Acceptances+at+EuroPCR+2026+Showcasing+Long-Term+Data+in+Pancreatic+Cancer+Pain+Mitigation/26510874.html <p align="justify"><b>THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=9noyMuXqnNSNADjktH47o0_hjHFgpuWHUtcodSKrbPGO57iCuAWKnyySONNhuYRwPnSxKMSikH4io5nRwNnzSajOf3x2KL61PgIGg4tHyR_essPZGfRGmF3ZBhBvRl9dindRlyslZ2DKOFF6KkGOCh4B-4LfbwrYx8-1cw_cSLi_pxUNoPJy95d1729Fcf5t8CPjTJvHU6D7X0yASDFkEsjrh0QNZcEn8W4j0cNGlEqzuFFjNbU-VFaiovlDyoMcLIBv0XJ-_1pR9CHYRTZulw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France.</p> <p align="justify">The accepted abstracts titled, <i>“Pain mitigation in pancreatic cancer: An analysis of denervation via transvascular RF ablation” and “Illuminating the nervous system with transvascular precision-guided technology”, </i>further recognize http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Announces+Abstract+Acceptances+at+EuroPCR+2026+Showcasing+Long-Term+Data+in+Pancreatic+Cancer+Pain+Mitigation/26510874.html Mon, 18 May 2026 08:45:00 -0400 AMIX O.58324469 http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Announces+Abstract+Acceptances+at+EuroPCR+2026+Showcasing+Long-Term+Data+in+Pancreatic+Cancer+Pain+Mitigation/26510874.html <p align="justify"><b>THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=9noyMuXqnNSNADjktH47o0_hjHFgpuWHUtcodSKrbPGO57iCuAWKnyySONNhuYRwPnSxKMSikH4io5nRwNnzSajOf3x2KL61PgIGg4tHyR_essPZGfRGmF3ZBhBvRl9dindRlyslZ2DKOFF6KkGOCh4B-4LfbwrYx8-1cw_cSLi_pxUNoPJy95d1729Fcf5t8CPjTJvHU6D7X0yASDFkEsjrh0QNZcEn8W4j0cNGlEqzuFFjNbU-VFaiovlDyoMcLIBv0XJ-_1pR9CHYRTZulw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France.</p> <p align="justify">The accepted abstracts titled, <i>“Pain mitigation in pancreatic cancer: An analysis of denervation via transvascular RF ablation” and “Illuminating the nervous system with transvascular precision-guided technology”, </i>further recognize http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Announces+Abstract+Acceptances+at+EuroPCR+2026+Showcasing+Long-Term+Data+in+Pancreatic+Cancer+Pain+Mitigation/26510874.html Mon, 18 May 2026 08:45:00 -0400 AMIX O.58324469 http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Announces+Abstract+Acceptances+at+EuroPCR+2026+Showcasing+Long-Term+Data+in+Pancreatic+Cancer+Pain+Mitigation/26510874.html <p align="justify"><b>THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=9noyMuXqnNSNADjktH47o0_hjHFgpuWHUtcodSKrbPGO57iCuAWKnyySONNhuYRwPnSxKMSikH4io5nRwNnzSajOf3x2KL61PgIGg4tHyR_essPZGfRGmF3ZBhBvRl9dindRlyslZ2DKOFF6KkGOCh4B-4LfbwrYx8-1cw_cSLi_pxUNoPJy95d1729Fcf5t8CPjTJvHU6D7X0yASDFkEsjrh0QNZcEn8W4j0cNGlEqzuFFjNbU-VFaiovlDyoMcLIBv0XJ-_1pR9CHYRTZulw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France.</p> <p align="justify">The accepted abstracts titled, <i>“Pain mitigation in pancreatic cancer: An analysis of denervation via transvascular RF ablation” and “Illuminating the nervous system with transvascular precision-guided technology”, </i>further recognize http://www.streetinsider.com/Press+Releases/Autonomix+Medical+Announces+Abstract+Acceptances+at+EuroPCR+2026+Showcasing+Long-Term+Data+in+Pancreatic+Cancer+Pain+Mitigation/26510874.html Mon, 18 May 2026 08:45:00 -0400 AMIX O.58324469 http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Announces+Abstract+Acceptances+at+EuroPCR+2026+Showcasing+Long-Term+Data+in+Pancreatic+Cancer+Pain+Mitigation/26510874.html <p align="justify"><b>THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) -- </b><a target="_blank" href="https://www.globenewswire.com/Tracker?data=9noyMuXqnNSNADjktH47o0_hjHFgpuWHUtcodSKrbPGO57iCuAWKnyySONNhuYRwPnSxKMSikH4io5nRwNnzSajOf3x2KL61PgIGg4tHyR_essPZGfRGmF3ZBhBvRl9dindRlyslZ2DKOFF6KkGOCh4B-4LfbwrYx8-1cw_cSLi_pxUNoPJy95d1729Fcf5t8CPjTJvHU6D7X0yASDFkEsjrh0QNZcEn8W4j0cNGlEqzuFFjNbU-VFaiovlDyoMcLIBv0XJ-_1pR9CHYRTZulw==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France.</p> <p align="justify">The accepted abstracts titled, <i>“Pain mitigation in pancreatic cancer: An analysis of denervation via transvascular RF ablation” and “Illuminating the nervous system with transvascular precision-guided technology”, </i>further recognize http://www.streetinsider.com/Globe+Newswire/Autonomix+Medical+Announces+Abstract+Acceptances+at+EuroPCR+2026+Showcasing+Long-Term+Data+in+Pancreatic+Cancer+Pain+Mitigation/26510874.html Mon, 18 May 2026 08:45:00 -0400 AMIX O.58324469